secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-05-21T22:02:43+00:00
Accession:  0001193125-26-234991
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports interim clinical data from three radiopharmaceutical programs at ASCO 2026
--------------------------------------------------------------------------------

- VMT01 in melanoma: 2/7 confirmed responses (29%) at 3.0 mCi; 6/7 stable disease or partial response.
- [212Pb]PSV359 advanced to Cohort 3 (6.0 mCi); no DLTs, grades 1-2 TEAEs only.
- VMT-α-NET: deepened responses vs prior cut-offs; 10/23 (43%) Cohort 2 patients achieved response per RECIST v1.1.
- All programs well-tolerated: no treatment-related discontinuations, no Grade 4/5 events across 68+ patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526234991/0001193125-26-234991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526234991/catx-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-234991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer